Sales of Pfizer's COVID-19 vaccine and treatment pushed the drugmaker well past expectations in the first quarter, as profit grew 61per cent.
The coronavirus vaccine Comirnaty brought in more than USD13 billion in sales, and the treatment Paxlovid added another USD1.5 billion as company revenue swelled 77per cent, the company said Tuesday.
Pfizer posted adjusted earnings of USD1.62 per share in the first quarter, on USD25.66 billion in revenue.
Analysts expected per-share earnings of USD1.49 on about USD24.1 billion in sales, according to FactSet.
Pfizer Inc., based in New York, also revised its 2022 earnings forecast to reflect an accounting policy change. It now expects adjusted earnings of USD6.25 to USD6.45 per share.
That's down from its previous forecast for USD6.35 to USD6.55 per share.
Analysts forecast earnings of USD7.14 per share.
Shares ticked slightly higher before the opening bell Thursday.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.